211 related articles for article (PubMed ID: 33252002)
1. Barriers, solutions, and effect of using pharmacogenomics data to support opioid prescribing.
Bright D; Petry N; Roath E; Reckow E; Chavour S
J Manag Care Spec Pharm; 2020 Dec; 26(12):1597-1602. PubMed ID: 33252002
[TBL] [Abstract][Full Text] [Related]
2. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
[TBL] [Abstract][Full Text] [Related]
3. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
Brown WC; Whitted K
J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
[TBL] [Abstract][Full Text] [Related]
4. Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.
Radomski TR; Bixler FR; Zickmund SL; Roman KM; Thorpe CT; Hale JA; Sileanu FE; Hausmann LRM; Thorpe JM; Suda KJ; Stroupe KT; Gordon AJ; Good CB; Fine MJ; Gellad WF
J Gen Intern Med; 2018 Aug; 33(8):1253-1259. PubMed ID: 29520747
[TBL] [Abstract][Full Text] [Related]
5. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
[TBL] [Abstract][Full Text] [Related]
6. Provider perceptions of system-level opioid prescribing and addiction treatment policies.
Haffajee RL; French CA
Curr Opin Psychol; 2019 Dec; 30():65-73. PubMed ID: 30856591
[TBL] [Abstract][Full Text] [Related]
7. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study.
Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ
Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575
[TBL] [Abstract][Full Text] [Related]
8. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
[TBL] [Abstract][Full Text] [Related]
9. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
[TBL] [Abstract][Full Text] [Related]
10. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012.
Perrone J; DeRoos FJ; Nelson LS
J Med Toxicol; 2012 Dec; 8(4):341-52. PubMed ID: 22895794
[TBL] [Abstract][Full Text] [Related]
11. Interstate data sharing of prescription drug monitoring programs and associated opioid prescriptions among patients with non-cancer chronic pain.
Lin HC; Wang Z; Simoni-Wastila L; Boyd C; Buu A
Prev Med; 2019 Jan; 118():59-65. PubMed ID: 30316875
[TBL] [Abstract][Full Text] [Related]
12. Prescription Drug Monitoring Programs Produce a Limited Impact on Painkiller Prescribing in Medicare Part D.
Yarbrough CR
Health Serv Res; 2018 Apr; 53(2):671-689. PubMed ID: 28101955
[TBL] [Abstract][Full Text] [Related]
13. Optimal Implementation of Prescription Drug Monitoring Programs in the Emergency Department.
Elder JW; DePalma G; Pines JM
West J Emerg Med; 2018 Mar; 19(2):387-391. PubMed ID: 29560070
[TBL] [Abstract][Full Text] [Related]
14. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids.
Wilson MP; Cucciare MA; Porter A; Chalmers CE; Mullinax S; Mancino M; Oliveto AH
Am J Emerg Med; 2020 Mar; 38(3):503-507. PubMed ID: 31221474
[TBL] [Abstract][Full Text] [Related]
15. The US Opioid Crisis: Current Federal and State Legal Issues.
Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
[TBL] [Abstract][Full Text] [Related]
16. Variations in prescription drug monitoring program use by prescriber specialty.
Sun BC; Lupulescu-Mann N; Charlesworth CJ; Kim H; Hartung DM; Deyo RA; John McConnell K
J Subst Abuse Treat; 2018 Nov; 94():35-40. PubMed ID: 30243415
[TBL] [Abstract][Full Text] [Related]
17. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
[TBL] [Abstract][Full Text] [Related]
18. Confronting challenges to opioid risk mitigation in the U.S. health system: Recommendations from a panel of national experts.
Finley EP; Schneegans S; Curtis ME; Bebarta VS; Maddry JK; Penney L; McGeary D; Potter JS
PLoS One; 2020; 15(6):e0234425. PubMed ID: 32542028
[TBL] [Abstract][Full Text] [Related]
19. Prescription Drug Monitoring Program Use: National Dental PBRN Results.
McCauley JL; Gilbert GH; Cochran DL; Gordan VV; Leite RS; Fillingim RB; Brady KT;
JDR Clin Trans Res; 2019 Apr; 4(2):178-186. PubMed ID: 30931705
[TBL] [Abstract][Full Text] [Related]
20. Engaging pharmacogenomics in pain management and opioid selection.
Bright DR; Petry N; Roath E; Gibb T
Pharmacogenomics; 2021 Sep; 22(14):927-937. PubMed ID: 34521258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
